Abstract

Abstract Background: Gynecological cancers (GC) involve female reproductive system malignancies, and acquired chemoresistance is a challenge in the treatment of GC. Protein deubiquitination, mediated by deubiquitinating enzymes (DUBs) like ubiquitin-specific proteases (USPs), holds therapeutic promise in cancer treatment. This study delves into the mechanistic understanding of DUBs, particularly in acquired chemoresistance in GC. Methodology: We initially examined TCGA database to assess the impact of Ubiquitin Specific Proteases (USPs), specifically USP37 and USP14, on prognosis in Gynaecological Cancers (GCs). Subsequently, we evaluated their expression in various GC cell lines at both protein and RNA levels. Cell proliferation and metastasis assays were performed to analyze the effect of depleting these USPs on survival and metastasis in GC cells under replication stress. Proteomics analysis was conducted on cells with altered expression of USP37 and USP14 to identify interacting proteins regulating proliferation and metastasis. To investigate DUBs role in chemoresistance, we generated chemoresistant (CR) cell lines with cisplatin exposure, characterized their viability and proliferation, conducted cell cycle and apoptosis analyses, and performed proteomic profiling to explore the USP37 and USP14 specific interactome in chemoresistant cell lines. Results: Examination of TCGA database revealed an association between elevated USP37 and USP14 expression and poor Overall Survival (OS) and Disease-free Survival (DFS) in Gynaecological Cancers (GC) cohort. Increased expression of USP37 and USP14 at RNA and protein levels was observed in GC cell lines. Inhibiting USP37 and USP14 reduced GC cell proliferation under replication stress and hindered metastasis. Proteomics analysis identified proteins linked to replication (PCNA), DNA damage (Chk-1), cell cycle, and metastasis. Cisplatin-resistant GC cell lines were successfully established, demonstrating prolonged survival and increased proliferative capacity after cisplatin treatment compared to chemosensitive (CS) cell lines. FACS analysis indicated altered cell cycle distribution and increased proliferation in CR cells. Comparative interactome analysis revealed altered protein sets associated with USP37 and USP14 in CR and CS GC cells. Conclusion: This study provides evidence that supports the participation of USP37 and USP14 in the onset of gynecological cancers (GC). We present evidence of alterations in the oncogenic network linked to USP37 and USP14 in GC. Additionally, we elucidate the roles of these deubiquitinating enzymes (DUBs) in chemoresistant cell lines. Citation Format: Ravi Chauhan, Ashna Gupta, Gunjan Dagar, Lakshay Malhotra, Ekta Rai, Muzafar A Macha, Ajaz A Bhat, Ethayathulla A Samath, Mayank Singh. Unraveling the oncogenic network of USP37 and USP14 in gynecological cancers: Decrypting the molecular landscape of chemoresistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4639.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call